High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers

Purpose Identification of single-gene biomarkers that are prognostic of outcome can shed new insights on the molecular mechanisms that drive breast cancer and other cancers. Methods Exploratory analysis of 20,464 single-gene messenger RNAs (mRNAs) in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) discovery cohort indicates that low expression of FGD3 mRNA is prognostic for poor outcome. Prognostic significance of faciogenital dysplasia 3 (FGD3), SUSD3, and other single-gene proliferation markers was evaluated in breast cancer and The Cancer Genome Atlas (TCGA) cohorts. Results A meta-analysis of Cox regression of FGD3 mRNA as a continuous variable for overall survival of estrogen receptor (ER)–positive samples in METABRIC discovery, METABRIC validation, TCGA breast cancer, and Combination Chemotherapy in Treating Women With Breast Cancer (E2197) cohorts resulted in a combined hazard ratio (HR) of 0.69 (95% CI, 0.63 to 0.75), indicating better outcome with high expression. In the ER-negative samples, the combined meta-analysis HR was 0.72 (95% CI, 0.63 to 0.82), suggesting that FGD3 is prognostic regardless of ER status. The potential of FGD3 as a biomarker for freedom from recurrence was evaluated in the Breast International Group 1-98 (BIG 1-98; Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer) study (HR, 0.85; 95% CI, 0.76 to 0.93) for breast cancer–free interval. In the Hungarian Academy of Science (HAS) breast cancer cohort, splitting on the median had an HR of 0.49 (95% CI, 0.42 to 0.58) for recurrence-free survival. A comparison of the Stouffer P value in five ER-positive cohorts showed that FGD3 (P = 3.8E-14) outperformed MKI67 (P = 1.06E-8) and AURKA (P = 2.61E-5). A comparison of the Stouffer P value in four ER-negative cohorts showed that FGD3 (P = 3.88E-5) outperformed MKI67 (P = .477) and AURKA (P = .820). Conclusion FGD3 was previously shown to inhibit cell migration. FGD3 mRNA is regulated by ESR1 and is associated with favorable outcome in six distinct breast cancer cohorts and four TCGA cancer cohorts. This suggests that FGD3 is an important clinical biomarker.

[1]  C. Lefebvre,et al.  Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis , 2016, PLoS medicine.

[2]  Wei Zhang,et al.  Proliferating Cell Nuclear Antigen Has an Association with Prognosis and Risks Factors of Cancer Patients: a Systematic Review , 2016, Molecular Neurobiology.

[3]  Carsten Denkert,et al.  Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group , 2016, Modern Pathology.

[4]  R. Kurzrock,et al.  Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. , 2015, Seminars in oncology.

[5]  Nuno A. Fonseca,et al.  Expression Atlas update—an integrated database of gene and protein expression in humans, animals and plants , 2015, Nucleic Acids Res..

[6]  C. Curtis.  Genomic profiling of breast cancers , 2015, Current opinion in obstetrics & gynecology.

[7]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Dimitris Anastassiou,et al.  Breast cancer prognostic biomarker using attractor metagenes and the FGD3-SUSD3 metagene. , 2014, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  C. Nelson,et al.  Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention , 2014, Front. Oncol..

[10]  Xiang-Sun Zhang,et al.  Breast tumor subgroups reveal diverse clinical prognostic power , 2014, Scientific Reports.

[11]  J. Coon,et al.  ESTROGEN-DEPENDENT SUSHI DOMAIN CONTAINING 3 REGULATES CYTOSKELETON ORGANIZATION AND MIGRATION IN BREAST CANCER CELLS , 2014, Oncogene.

[12]  Jan Budczies,et al.  Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.

[13]  Tai-Hsien Ou Yang,et al.  Development of a Prognostic Model for Breast Cancer Survival in an Open Challenge Environment , 2013, Science Translational Medicine.

[14]  V. Theodorou,et al.  GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility , 2013, Genome research.

[15]  KyungMann Kim,et al.  Contrasting treatment‐specific survival using double‐robust estimators , 2012 .

[16]  Andreas Prlic,et al.  BioJava: an open-source framework for bioinformatics in 2012 , 2012, Bioinform..

[17]  E. Génot,et al.  FGD1 as a central regulator of extracellular matrix remodelling – lessons from faciogenital dysplasia , 2012, Journal of Cell Science.

[18]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[19]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[20]  Z. Szallasi,et al.  Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. , 2012, Endocrine-related cancer.

[21]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[22]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[23]  E. Génot,et al.  The Aarskog-Scott Syndrome Protein Fgd1 Regulates Podosome Formation and Extracellular Matrix Remodeling in Transforming Growth Factor β-Stimulated Aortic Endothelial Cells , 2011, Molecular and Cellular Biology.

[24]  D. Zaykin,et al.  Optimally weighted Z‐test is a powerful method for combining probabilities in meta‐analysis , 2011, Journal of evolutionary biology.

[25]  Y. Luqmani,et al.  Estrogen Receptor Silencing Induces Epithelial to Mesenchymal Transition in Human Breast Cancer Cells , 2011, PloS one.

[26]  Yuan Qi,et al.  Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. , 2010, Cancer research.

[27]  Jon W. Huss,et al.  BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources , 2009, Genome Biology.

[28]  A. Luini,et al.  Faciogenital dysplasia protein (FGD1) regulates export of cargo proteins from the golgi complex via Cdc42 activation. , 2009, Molecular biology of the cell.

[29]  V. Castronovo,et al.  Faciogenital dysplasia protein Fgd1 regulates invadopodia biogenesis and extracellular matrix degradation and is up-regulated in prostate and breast cancer. , 2009, Cancer research.

[30]  Andreas Prlic,et al.  Sequence analysis , 2003 .

[31]  M. Kitagawa,et al.  Novel insights into FGD3, a putative GEF for Cdc42, that undergoes SCFFWD1/β‐TrCP‐mediated proteasomal degradation analogous to that of its homologue FGD1 but regulates cell morphology and motility differently from FGD1 , 2008, Genes to cells : devoted to molecular & cellular mechanisms.

[32]  Suhail A R Doi,et al.  A Quality-Effects Model for Meta-Analysis , 2008, Epidemiology.

[33]  Yehia Mechref,et al.  A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker , 2006, Proceedings of the National Academy of Sciences.

[34]  Johannes Gerdes,et al.  Ki‐67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells , 2006, Journal of cellular physiology.

[35]  M. Whitlock.  Combining probability from independent tests: the weighted Z‐method is superior to Fisher's approach , 2005, Journal of evolutionary biology.

[36]  M. Pencina,et al.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation , 2004, Statistics in medicine.

[37]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Ruderman,et al.  Aurora A, Meiosis and Mitosis , 2004, Biology of the cell.

[39]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[40]  E. Suchman,et al.  The American Soldier: Adjustment During Army Life. , 1949 .

[41]  K. Ando,et al.  Proline-rich domain plays a crucial role in extracellular stimuli-responsive translocation of a Cdc42 guanine nucleotide exchange factor, FGD1. , 2010, Biological & pharmaceutical bulletin.

[42]  M. Karin,et al.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.